Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz, Iran

Maral Gharaghani1, Marzieh Halvaezadeh1, 2, Gholam Ali Jalae4, Simin Taghipour2, Neda Kiasat2, Ali Zarei Mahmoudabadi1, 2*

1Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3Otorhinolaryngologist, Apadana Hospital, Sorosh Street, Ahvaz, Iran

Article Info
Article type: Original article

Article History:
Received: 05 December 2019
Revised: 07 February 2020
Accepted: 09 March 2020

* Corresponding author:
Ali Zarei Mahmoudabadi
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Email: zarei40@hotmail.com

Abstract

Background and Purpose: Otomycosis is a secondary ear fungal infection among predisposed individuals in humid conditions. Aspergillus species are the most common etiologic agents of this infection. Several ototopical antifungals are currently used for the treatment of this disease; however, recurrence and treatment failure are usually observed in some cases. Regarding this, the present study was conducted to investigate the antifungal activity of caspofungin, azoles, and terbinafine against the isolated agents of otomycosis.

Materials and Methods: This study was conducted on the specimens collected from 90 patients with otomycosis. The samples were cultured on Sabouraud dextrose agar and identified based on morphological characteristics, physiological tests, and microscopic features. Furthermore, the microdilution method was used for antifungal susceptibility testing according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Finally, the minimum inhibitory concentration (MIC) and minimum effective concentration (MEC) ranges, MIC/MEC, and geometric mean (GM) MIC/MEC were calculated for the isolates.

Results: According to the results, 77 patients with otomycosis were positive for different Aspergillus (88.3%) and Candida (11.7%) species. Aspergillus niger complex (n=36) was found to be the most common agent, followed by A. flavus, A. terreus, and A. nidulans complexes. Furthermore, epidemiological cutoff values (ECVs) were lower than those presented by the CLSI for itraconazole and caspofungin in 98.5% and 42.6% of Aspergillus species, respectively. Terbinafine exhibited a great activity against Aspergillus species, while fluconazole revealed a low activity against both Aspergillus species. Based on the results, 77.8% of Candida species were resistant to caspofungin; however, miconazole and econazole had low MIC ranges.

Conclusion: Aspergillus niger and A. flavus complexes were identified as the most common agents accounting for 85.7% of the isolates. In addition, terbinafine was identified as the best antifungal for both Aspergillus and Candida species. Moreover, tested azoles had relatively low MICs, whereas most of the isolates had the MIC values beyond the caspofungin ECVs.

Keywords: Antifungals, Aspergillus species, Caspofungin, Otomycosis

Introduction

Otomycosis, an acute to chronic fungal infection, is often considered a secondary outer ear fungal infection, including the auricle and external auditory canal. This disease also affects the tympanic membrane in some cases as a result of disease extension. However, the middle ear is rarely infected by the causative agents of otomycosis. The most common symptoms of this disease include itching, pain, redness, swelling, ear discharge, and ear fullness with gradual hearing loss.

Although the anatomy of the ear canal acts as a route and residence of fungal elements, tropical conditions, trauma, bacterial otitis, ear anomalies, and hearing aids are predisposing factors for otomycosis [1, 2]. On the other hand, low socioeconomic status and occupation (involving exposure to dusty and fungal contaminants) have an important role in the occurrence of this disease in a tropical climate [3, 4]. Recently, diabetes, steroid administration, HIV infection, chemotherapy, several malignancies, and invasive therapies were also added to the list of otomycosis predisposing factors [5].
Several species of saprophytic fungi, including molds, yeasts, and rarely dermatophytes, are involved in the development of otomycosis. However, the species of the genus *Aspergillus*, especially *Aspergillus niger* complex, are the most common causative agents of this infection, with a worldwide distribution [3, 6]. In a review study conducted on Iranian studies, Gharaghani et al. reported *A. niger* as the most common etiological agent of otomycosis (51.15%) in Iran, followed by *A. flavus* (17.03%), *Candida albicans* (11.39%), *A. fumigatus* (7.33%), and other species (13.1%) [3, 7-9]. Although the majority of otomycosis cases are usually caused by *Aspergillus* species, different *Candida* species play an important role in the disease as endogenous organisms [7, 8]. *Candida* species have been reported as the second most common otomycosis agents; in this regard, *C. albicans* was recognized as the most common agent [4, 8, 10]. Furthermore, the rare cases of otomycosis due to dermatophytes and *Malassezia* species have been also reported by researchers [4].

The elimination and/or control of predisposing factors and antifungal therapy are necessary for the complete treatment of otomycosis. Topical antifungals, such as clotrimazole, miconazole, econazol, and nystatin, are specific agents for the treatment of otomycosis [11, 12]. However, the increasing resistance to antifungals underscores the need for the development of new antifungals. Furthermore, the investigation of new antifungal drugs is an interesting area for many of the mycologists and clinicians. Caspofungin, a new antifungal with fungicidal activity, is used for the treatment of invasive aspergillosis [13] and candidiasis [14]. In addition, some studies have tested the activities of this antifungal against the different species of *Aspergillus* and obtained effective potential [15-17]. With this background in mind, the present study was conducted to isolate, identify, and study the antifungal activity of caspofungin, miconazole, fluconazole, terbinafine, econazol, bifonazole, and itraconazole against the causative agents of otomycosis.

Materials and Methods

Patients and sampling

For the purpose of the study, 90 patients suspected of having otomycosis were physically examined by an otorhinolaryngologist. Clinical specimens (i.e., debris and pus) were collected from the patient’s ears using moisture swabs. The swabs were cultured on the slants of Sabouraud dextrose agar (SDA; Merck, Germany) and incubated at 27-29°C for a week. Cultures were examined daily, and all grown fungi subcultured on two fresh SDA slants were preserved at ambient temperature until use.

Identification of causative agents

All recovered fungi were primarily subcultured on fresh SDA slants. The yeast isolates were detected using germ tube formation, growth at 42-45°C, morphology on Cornmeal agar (HighMedia, India) supplemented with 1% Tween 80 (Merck, Germany), and colony coloration on CHROMagar *Candida* (CHROMagar Candida, France). Moreover, the colony morphology characteristics and microscopic features were used for *Aspergillus* species.

Standard suspension preparation

In order to prepare a standard suspension, each of the tested isolates was cultured on SDA for 48-72 h at 35°C. A suspension of spores was prepared in 0.85% NaCl, containing 0.05% Tween 20, adjusted to 0.5 McFarland according to the CLSI M38 3rd edition, and then diluted at a ratio of 1:50 [18]. Moreover, a suspension of yeast colonies was prepared in sterile distilled water, adjusted to 0.5 McFarland based on the CLSI M27 4th edition, and then diluted at a ratio of 1:1000 [19].

Susceptibility assessment

Antifungal susceptibility assay was performed based on the microdilution method (96-well microdilution plates), using the CLSI M38 3rd edition and M27 4th edition for molds and yeasts, respectively [18, 19]. A serial dilution of antifungals was prepared in RPMI 1640 (Bio-Idea, Iran), including miconazole (0.0312-16 μg/mL), fluconazole (0.25-128 μg/mL), terbinafine (0.0156-8 μg/mL), caspofungin (0.0156-8 μg/mL), econazole (0.0156-8 μg/mL), bifonazole (0.0312-16 μg/mL), and itraconazole (0.0156-8 μg/mL). According to the CLSI instruction, 100 μL of each antifungal dilution and 100 μL of standard suspension were added to each well. Negative and positive controls were a well-contained RPMI 1640 without fungal spores and antifungals and a well-contained RPMI 1640 with fungal spores and without antifungals, respectively.

The microplates were incubated at 35°C for 24 h and minimum inhibitory concentration (MIC) was read for 48 h (when the control well showed insufficient growth) for yeasts and molds. Then MIC range, MIC50, MIC90, and geometric mean (GM) MIC were calculated for the isolates. With regard to caspofungin, minimum effective concentration (MEC) range, MEC50, MEC90, and GM MEC were calculated for *Aspergillus* isolates. In the present study, susceptibility/resistance of the strains to each antifungal was evaluated according to the breakpoints and epidemiologic cutoff values (ECVs) defined by the CLSI and/or several researchers [20-22].

Ethical consideration

This study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (IR.AJUMS.REC.1394.118). In addition, all patients or parents signed a consent form before sampling.

Results

In the present study, 77 (85.6%) of the 90
specimens obtained from the patients with otomycosis were positive for different Aspergillus (n=68, 88.3%) and Candida (n=9, 11.7%) strains. A total of 36 isolates belonged to A. niger complex as the most common causative agent, followed by A. flavus complex (n=30), A. terreus complex (n=1), and A. nidulans complex (n=1). Moreover, 9 isolates of Candida, including C. albicans, C. glabrata, and Candida species (every 3 isolates), were identified in the samples.

Table 1 presents the in vitro antifungal susceptibility results of 7 antifungals against Aspergillus species. Terbinafine exhibited a great activity in vitro with the GM MIC values of 0.10509 and 0.17678 μg/mL against A. niger complex and A. flavus complex isolates, respectively. Moreover, MIC values for terbinafine ranged within 0.00312-1 μg/mL, indicating that all isolates were sensitive to this antifungal at ≥ 1 μg/mL. In the present study, 98.5% and 42.6% of Aspergillus species had ECVs lower than those presented by the CLSI [21, 22].

Aspergillus niger complex (36)
- Terbinafine: MIC 0.0312-0.5 μg/mL, MIC₉₀ 0.5 μg/mL, MIC₅₀ 0.0625 μg/mL, MIC₅₀ 0.01059 μg/mL
- Caspofungin: MIC 0.0312-8 μg/mL, MIC₉₀ 8 μg/mL, MIC₅₀ 0.12444 μg/mL
- Fluconazole: MIC 1-128 μg/mL, MIC₉₀ 128 μg/mL, MIC₅₀ 50.79683 μg/mL
- Itraconazole: MIC 0.0312-2 μg/mL, MIC₉₀ 2 μg/mL, MIC₅₀ 0.39641 μg/mL
- Miconazole: MIC 0.25-4 μg/mL, MIC₉₀ 4 μg/mL, MIC₅₀ 0.98768 μg/mL
- Bifonazole: MIC 0.0312-2 μg/mL, MIC₉₀ 2 μg/mL, MIC₅₀ 0.29671 μg/mL
- Econazole: MIC 0.0625-0.5 μg/mL, MIC₉₀ 0.125 μg/mL, MIC₅₀ 0.07577 μg/mL

A. flavus complex (30)
- Terbinafine: MIC 0.0625-1 μg/mL, MIC₉₀ 1 μg/mL, MIC₅₀ 0.17678 μg/mL
- Caspofungin: MIC 0.0312-8 μg/mL, MIC₉₀ 8 μg/mL, MIC₅₀ 3.24849 μg/mL
- Fluconazole: MIC 1-128 μg/mL, MIC₉₀ 128 μg/mL, MIC₅₀ 64 μg/mL
- Itraconazole: MIC 0.0312-2 μg/mL, MIC₉₀ 2 μg/mL, MIC₅₀ 0.30777 μg/mL
- Miconazole: MIC 0.25-8 μg/mL, MIC₉₀ 8 μg/mL, MIC₅₀ 4.02337 μg/mL
- Bifonazole: MIC 0.0312-2 μg/mL, MIC₉₀ 2 μg/mL, MIC₅₀ 1.58732 μg/mL
- Econazole: MIC 0.0312-0.25 μg/mL, MIC₉₀ 0.25 μg/mL, MIC₅₀ 0.10389 μg/mL

Aspergillus terreus complex (1)
- Terbinafine: MIC 0.25 μg/mL
- Caspofungin: MIC 8 μg/mL
- Fluconazole: MIC 16 μg/mL
- Itraconazole: MIC 0.25 μg/mL
- Miconazole: MIC 1 μg/mL
- Bifonazole: MIC 0.5 μg/mL
- Econazole: MIC 0.125 μg/mL

A. nidulans complex (1)
- Terbinafine: MIC 1 μg/mL
- Caspofungin: MIC 0.125 μg/mL
- Fluconazole: MIC 128 μg/mL
- Itraconazole: MIC 0.125 μg/mL
- Miconazole: MIC 1 μg/mL
- Bifonazole: MIC 2 μg/mL
- Econazole: MIC 0.125 μg/mL

Table 2 presents the details related to the antifungal susceptibility of Candida species. According to the breakpoints presented by the CLSI [21, 22], most of the isolates (77.8%) were resistant to caspofungin, fluconazole, and itraconazole, respectively.

Table 2. Antifungal susceptibility of otomycosis agents (Candida species)

| Species | Antifungals | MIC | Resistant (%) |
|---------|-------------|-----|---------------|
| Candida albicans (3) | Terbinafine | 2-8 μg/mL | 0 (0.0%) |
| | Caspofungin | 0.5-2 μg/mL | 0 (0.0%) |
| | Fluconazole | 4-16 μg/mL | 1 (33.3%) |
| | Itraconazole | 0.5-4 μg/mL | 0 (0.0%) |
| | Miconazole | 0.5-4 μg/mL | 1 (100%) |
| | Bifonazole | 3-16 μg/mL | 0 (0.0%) |
| | Econazole | 0.0625-0.5 μg/mL | 0 (0.0%) |
| C. glabrata (3) | Terbinafine | 0.0625-1 μg/mL | 0 (0.0%) |
| | Caspofungin | 1-2 μg/mL | 0 (0.0%) |
| | Fluconazole | 0.0625-0.5 μg/mL | 0 (0.0%) |
| | Itraconazole | 4-16 μg/mL | 0 (0.0%) |
| | Miconazole | 2-8 μg/mL | 0 (0.0%) |
| | Bifonazole | 0.0625-1 μg/mL | 0 (0.0%) |
| Candida species (3) | Terbinafine | 0.0625-8 μg/mL | 0 (0.0%) |
| | Caspofungin | 0.5-2 μg/mL | 7 (77.8%) |
| | Fluconazole | 1-32 μg/mL | 3 (100%) |
| | Itraconazole | 0.0625-8 μg/mL | 3 (100%) |
| | Miconazole | 0.25-4 μg/mL | 0 (0.0%) |
| | Bifonazole | 2-16 μg/mL | 0 (0.0%) |
| | Econazole | 0.0625-1 μg/mL | 0 (0.0%) |

ECV: epidemiologic cutoff values, ND: not determined

* %MICs less than or equal to the ECVs (ECV=1-2 μg/mL for itraconazole, 0.06-0.12 μg/mL for caspofungin)
* % Minimum effective concentration (MEC, MEC₉₀, MEC₅₀, and MEC₅₀) were calculated for organisms.
followed by fluconazole (33.3%) and itraconazole (33.3%). Although both azoles (i.e., miconazole and econazole) had low MIC ranges (i.e., 0.25-4 and 0.0625-1 µg/mL, respectively), the MIC range for bifonazole was 2-16 µg/mL.

Discussion

Otomycosis is one of the problematic infectious diseases among tropical and subtropical inhabitants, posing diagnostic and therapeutic challenges to patients, clinicians, and laboratory workers. Several antifungal agents, including clotrimazole, miconazole, ketoconazole, itraconazole, lanocozole, voriconazole, fluconazole, and nystatin, have been used for the treatment of otomycosis [9, 10, 23, 24]. However, there are still unresponded/persistent and recurrent cases of otomycosis as reported by several researchers [24, 25]. Moreover, the literature is indicative of the in vitro resistance of the causative agents of this disease against antifungal agents [26, 27].

There are a few studies in the literature investigating the activity of terbinafine against Aspergillus species with otomycosis sources. In a study performed by Karaarslan et al., Aspergillus species (i.e., A. niger, A. flavus, and A. terreus) isolated from otomycosis was reported to exhibit a relatively low MIC range (0.03-25 µg/mL) for terbinafine [28]. This observation agrees with our results showing the inhibition of A. niger complex strains by terbinafine at a MIC range of 0.0312-0.5 µg/mL. However, in the present study, the MIC range of A. flavus complex was slightly higher (0.0625-1 µg/mL). Alcazar-Fuoli et al. reported a low MIC value (0.07-1.17 µg/mL) for terbinafine against black Aspergilli obtained from different clinical specimens [29]. Moreover, in a study carried out by Zarei Mahmoudabadi et al., terbinafine was reported to be the best antifungal against the causative agent of otomycosis [30].

Different results have been reported for the efficacy of caspofungin against Aspergillus species. In the present study, 57.4% of Aspergillus isolates were resistant to caspofungin. Nonetheless, in a study performed by Pfaller et al., 100% of Aspergillus strains were inhibited by caspofungin at the MEC range of 0.007-0.12 µg/mL [31]. Moreover, Arikand et al. reported the MEC range of 0.25-1 µg/mL for caspofungin against different Aspergillus species [32]. In addition, our results revealed that 58.3% of A. niger complex had the ECVs lower than the values defined by CLSI in comparison to A. flavus complex (23.3%).

Yenisehirli et al. and Szigeti et al. reported resistance to fluconazole in all of the Aspergillus strains recovered from otomycosis with a high MIC value (≥256 and >64 µg/mL) [6, 33]. Nevertheless, in the current research, only 36.8% of our Aspergillus isolates were resistant to this azole. In addition, in our study, the MIC value ranges showed that Aspergillus species were inhibited by itraconazole (<8 µg/mL), and only one strain of A. flavus complex was resistant to this antifungal (≥8). Similarly, Yenisehirli et al. and Diekema et al. found that all of their Aspergillus species were sensitive to itraconazole [17, 33]. Miconazole, bifonazole, and econazole had a low MIC range against A. niger complex, A. terreus complex, and A. nidulans complex strains. However, the MIC range was slightly higher for A. flavus complex isolates. Ahmed et al. showed that 76% of Aspergillus isolates from patients with otomycosis were sensitive to miconazole based on the disk diffusion method [34].

The present study involved the examination of a few strains of Candida, causing otomycosis, against several antifungals. The results revealed that most of the isolates (77.8%) were resistant to caspofungin. In a study carried out by Pfaller et al., 99.7% of Candida species (from blood or normally sterile sites) were inhibited at a caspofungin MIC of < 1 µg/mL [35]. It seems that the sources of isolation could affect their susceptibility to caspofungin. In line with the results obtained by Szigeti et al., our results showed that all Candida isolates were highly susceptible to terbinafine [6]. In addition, 33.3% of the tested isolates were resistant to both fluconazole and itraconazole, while the MIC ranges for econazole, miconazole, and bifonazole were low, medium, and high, respectively.

Conclusion

As the findings of the present study indicated, A. niger and A. flavus were identified as the most common otomycotic fungal pathogen complexes by accounting for 85.7% of the isolates. According to the susceptibility assay, terbinafine was the best antifungal for otomycosis agents (i.e., both Aspergillus and Candida species). Moreover, azoles, such as itraconazole, econazole, miconazole, and bifonazole, were found to have relatively low MICs. In contrast, most of the isolates were out of the defined ECVs for caspofungin.

Acknowledgments

We are thankful to the Health Research Institute, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, for their contribution. This research was supported by a grant (No: OG-93126) from the Ahvaz Jundishapur University of Medical Sciences.

Author’s contribution

A. Z. M. designed the study, analyzed the data, and wrote the manuscript. G. A. J. examined and sampled the patients. M. G., M. H., S. T., and N. K. performed data collection and analysis.

Conflicts of interest

The authors declare that they have no conflict of interest regarding the publication of this article.

Financial disclosure

No financial interests related to the material of this manuscript have been declared.
1. Kissiourri K, Rajabnia R, Jallili B, Khafri S, Omran SM. Otomycosis in adolescent patients referred to the therapeutic centers in Babol city, Iran. Jundishapur J Microbiol. 2015; 8(5):e17138.

2. Zarei Mahmoudabadi A, Abshirini H, Rahimi R. Fungal flora of hearing aid moulds and ear canal in hearing aid wearers in school children in Ahvaz, Iran (2008). Jundishapur J Microbiol. 2009; 2(1):22-4.

3. Gharaghani M, Seifi Z, Zarei Mahmoudabadi A. Otomycosis in Iran: a review. Mycopathologia. 2015; 179(5-6):415-24.

4. Kazemi A, Majdindia M, Jafarri A, Ayatollahi Mousavi SA, Zarei Mahmoudabadi A, Alkhhah H. Etiologic agents of otomycosis in the north-western area of Iran. Jundishapur J Microbiol. 2015; 8(9):e21776.

5. Viswanatha B, Naseeruddin K. Fungal infections of the ear in immunocompromised host: a review. Medit J Hematol Infect Dis. 2011; 3(1):e2011003.

6. Szeguti G, Sedaghati E, Mahmoudabadi AZ, Naseri A, Kocsube S, Vagvolgyi C, et al. Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran. Mycoses. 2012; 55(4):333-8.

7. Abastabar M, Haghani I, Ahangarkani F, Rezai MS, Taghizadeh Armaki M, Roodgari S, et al. Candida auris otomycosis in Iran and review of recent literature. Mycoses. 2019; 62(2):101-5.

8. Barati B, Okhovvat SA, Goljanian A, Omranii MR. Otomycosis in central Iran: a clinical and mycological study. Iran Red Crescent Med J. 2011; 13(12):873-6.

9. Ho T, Vrabec JT, Yoo D, Coker NJ. Otomycosis: clinical features and treatment implications. Otolaryngol head Neck Surg. 2006; 135(5):787-91.

10. Vennewald I, Klemm E. Otomycosis: diagnosis and treatment. Clin Dermatol. 2010; 28(2):202-11.

11. Khan F, Muhammad R, Khan MR, Rehman F, Iqbal J, Khan M, et al. Efficacy of topical clotrimazole in treatment of otomycosis. J Ayub Med College, Abbottabad. 2013; 25(1-2):78-80.

12. Ologe F, Wabausi C. Treatment outcome of otomycosis in Ilorin, Nigeria. West Afr J Med. 2001; 20(1):34-6.

13. Maertens J, Raad I, Petrikos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004; 39(11):1563-71.

14. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347(25):2020-9.

15. Badali H, Fakhm H, Zarei F, Nabili M, Vaezi A, Poorzad N, et al. In vitro activities of five antifungal drugs against opportunistic agents of Aspergillus niger complex. Mycopathologia. 2016; 181(3-4):235-40.

16. Kahn JN, Hsu MJ, Racine F, Gaicobbe R, Motyl M. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucon synthase and reduction of β-d-1, 3 glucan levels in culture. Antimicrob Agents Chemother. 2006; 50(6):2214-6.

17. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaffer MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003; 41(8):3623-6.

18. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; CLSI document M38-3rd. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

19. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; CLSI standard M27. 4th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

20. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaffer MA, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010; 48(9):3251-7.

21. Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing; CLSI supplement M39. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

22. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.

23. Munguia R, Daniel SJ. Ototopical antifungals and otomycosis: a review. Int J Pediatr Otorhinolaryngol. 2008; 72(4):453-9.

24. Chappe M, Vrignaud S, de Gentile L, Legrand G, Lagarce F, Le Govic Y. Successful treatment of a recurrent Aspergillus niger otomycosis with local application of voriconazole. J Mycol Med. 2018; 28(2):36-9.

25. Jia X, Liang Q, Chi F, Cao W. Otomycosis in Shanghai: aetiology, clinical features and therapy. Mycoses. 2012; 55(5):404-9.

26. Nemati S, Hassanzadeh R, Khajeh Jahromi S, Delkhosh Nasrollah Abadi A. Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents. Eur Arch Otorhinolaryngol. 2014; 271(5):953-7.

27. Saunders JE, Raju RP, Boone JL, Hales NW, Berryhill WE. Antibiotic resistance and otomycosis in the draining ear: culture results by diagnosis. Am J Otolaryngol. 2011; 32(6):470-6.

28. Karraya A, Arifka S, Ozcan M, Ozcan KM. In vitro activity of terbinfine and itraconazole against Aspergillus species isolated from otomycosis. Mycoses. 2004; 47(7):284-7.

29. Alhazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother. 2009; 53(10):4514-7.

30. Zarei Mahmoudabadi A, Seifi Z, Gharaghani M, Lamsili, a potent alternative antifungal drug for otomycosis. Curr Med Mycol. 2015; 1(1):18-21.

31. Pfaffer M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to itraconafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol. 2009; 47(10):3323-5.

32. Arifka S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against aspergillus and fusarium isolates. Antimicrob Agents Chemother. 2001; 45(1):327-30.

33. Yenisehirli G, Bulut Y, Guven M, Gunday E. In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens. J Laryngol Otol. 2009; 123(9):978-81.

34. Ahmed MR, Abou-Halawa AS, Hessam WF, Abdelkader DS. A search for new otomycotic species and their sensitivity to different antifungals. Interv Med Appl Sci. 2018; 10(3):145-9.

35. Pfaffer M, Boyken L, Hollis R, Messer S, Tendolkar S, Diekema D. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol. 2006; 44(3):760-3.